BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trivioli G, Terrier B, Vaglio A. Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. Rheumatology (Oxford) 2020;59:iii84-94. [PMID: 32348510 DOI: 10.1093/rheumatology/kez570] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Ríos-Garcés R, Prieto-González S, Hernández-Rodríguez J, Arismendi E, Alobid I, Penatti AE, Cid MC, Espígol-Frigolé G. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. Eur J Intern Med 2021:S0953-6205(21)00294-6. [PMID: 34535374 DOI: 10.1016/j.ejim.2021.08.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu S, Han L, Liu Y, Yang J, Zhang Y, Li M, Tian X, Zeng X, Wang L, Zhang F. Clinical Significance of MPO-ANCA in Eosinophilic Granulomatosis With Polyangiitis: Experience From a Longitudinal Chinese Cohort. Front Immunol 2022;13:885198. [DOI: 10.3389/fimmu.2022.885198] [Reference Citation Analysis]
3 Wang CR, Tsai YS, Tsai HW, Lee CH. B-Cell-Depleting Therapy Improves Myocarditis in Seronegative Eosinophilic Granulomatosis with Polyangiitis. J Clin Med 2021;10:4577. [PMID: 34640595 DOI: 10.3390/jcm10194577] [Reference Citation Analysis]
4 Niccolai E, Bettiol A, Baldi S, Silvestri E, Di Gloria L, Bello F, Nannini G, Ricci F, Nicastro M, Ramazzotti M, Vaglio A, Bartolucci G, Emmi G, Amedei A, Prisco D. Gut Microbiota and Associated Mucosal Immune Response in Eosinophilic Granulomatosis with Polyangiitis (EGPA). Biomedicines 2022;10:1227. [DOI: 10.3390/biomedicines10061227] [Reference Citation Analysis]
5 Akiyama M, Takanashi S, Takeuchi T, Kaneko Y. Salivary gland involvement in ANCA-associated vasculitis. Autoimmun Rev 2021;20:102940. [PMID: 34509652 DOI: 10.1016/j.autrev.2021.102940] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Vaglio A, Maritati F, Zwerina J. Response to: 'Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease' by Akiyama et al. Ann Rheum Dis 2020:annrheumdis-2020-218174. [PMID: 32591358 DOI: 10.1136/annrheumdis-2020-218174] [Reference Citation Analysis]
7 Higashitani K, Yoshimi R, Sato Y, Watanabe T, Ihata A. Rituximab and Mepolizumab Combination Therapy for Glucocorticoid-Resistant Myocarditis Related to Eosinophilic Granulomatosis With Polyangiitis. Mod Rheumatol Case Rep 2021:rxab022. [PMID: 34473835 DOI: 10.1093/mrcr/rxab022] [Reference Citation Analysis]
8 Yamashita Y, Takeichi T, Ishizu Y, Suzuki N, Tsuboi T, Matsuura K, Koizumi H, Muro Y, Akiyama M. Eosinophilic granulomatosis with polyangiitis complicated with idiopathic thrombocytopenic purpura and sclerosing cholangitis showing eosinophilic infiltration. J Dermatol 2022. [PMID: 35445420 DOI: 10.1111/1346-8138.16399] [Reference Citation Analysis]
9 Jin K, Parreau S, Warrington KJ, Koster MJ, Berry GJ, Goronzy JJ, Weyand CM. Regulatory T Cells in Autoimmune Vasculitis. Front Immunol 2022;13:844300. [DOI: 10.3389/fimmu.2022.844300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Egan AC, Smith RM, Jayne DRW. Introduction to the European Vasculitis Society 3rd International Vasculitis Course (Cambridge) case-based supplement. Rheumatology (Oxford) 2021;60:iii1-5. [PMID: 34137887 DOI: 10.1093/rheumatology/keab331] [Reference Citation Analysis]
11 Mescia F, Egan AC, Cheema K, Sivasothy P, Jayne DRW. Eosinophilic granulomatosis with polyangiitis present and future. Rheumatology (Oxford) 2021;60:iii24-7. [PMID: 34137880 DOI: 10.1093/rheumatology/keab033] [Reference Citation Analysis]
12 Akiyama M, Kaneko Y, Takeuchi T. Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease. Ann Rheum Dis. [DOI: 10.1136/annrheumdis-2020-218124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Pagnoux C, Fifi-mah A. Update on Maintenance Therapies for ANCA-Associated Vasculitis. Curr Treat Options in Rheum 2021;7:112-33. [DOI: 10.1007/s40674-021-00176-z] [Reference Citation Analysis]
14 Guillevin L. Treatment of systemic necrotizing vasculitides: The 40-year experience of the French Vasculitis Study Group. Presse Med 2020;49:104034. [PMID: 32650043 DOI: 10.1016/j.lpm.2020.104034] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Aso K, Fujieda Y, Atsumi T. Reversible Diffuse Bronchial Wall Thickening. Intern Med 2022. [PMID: 35650132 DOI: 10.2169/internalmedicine.9555-22] [Reference Citation Analysis]
16 Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review. Autoimmun Rev 2021;20:102737. [PMID: 33340770 DOI: 10.1016/j.autrev.2020.102737] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Sato M, Yoshida Y, Sugimoto T, Kishimoto S, Omoto T, Watanabe H, Tokunaga T, Yukawa K, Kohno H, Mokuda S, Nojima T, Hirata S, Sugiyama E. Asymptomatic coronary aneurysms in a patient with eosinophilic granulomatosis with polyangiitis who developed a digital gangrene. Mod Rheumatol Case Rep 2021;5:130-6. [PMID: 32791887 DOI: 10.1080/24725625.2020.1810404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Ishida T, Murayama T, Kobayashi S. Pneumonia and seizures due to hypereosinophilic syndrome—organ damage and eosinophilia without synchronisation: A case report. World J Clin Cases 2022; 10(18): 6325-6332 [DOI: 10.12998/wjcc.v10.i18.6325] [Reference Citation Analysis]